The patent has been licensed worldwide, with the exception of Australia and New Zealand, to the recently formed soy ingredients business Solae, a joint venture between DuPont and Bunge.
The patent has prompted Solae to issue a new patent infringement suit in the US against both Archer Daniels Midland and Amerfit.
Novogen, which also develops pharmaceutical products, already holds a number of US patents for technology for the production of isoflavones and also markets its own proprietary supplements - Promensil, for the treatment of the symptoms of menopause, Rimostil for the maintenance of bone and cholesterol health in post-menopausal women and Trinovin for the maintenance of prostate and urinary health for men.
It has been receiving royalty payments from Solae for some months for licensing part of its technology to DuPont.